Progenics also announced positive preliminary results of a phase I clinical study of a new oral formulation of methylnaltrexone, conducted by Wyeth. The trial is a double-blind, randomized single-dose crossover pharmacokinetic/pharmacodynamic study in subjects receiving methadone(Drug information on methadone), an opioid used to treat addiction.According to the companies, a substantial majority of patients experienced a bowel movement after receiving the higher of two doses of oral methylnaltrexone. The formulation was generally well tolerated. Based on these findings, the companies plan to conduct further clinical testing of new oral formulations.
